Copyright: ©Author(s) 2026.
World J Nephrol. Sep 25, 2026; 15(3): 120318
Published online Sep 25, 2026. doi: 10.5527/wjn.v15.i3.120318
Published online Sep 25, 2026. doi: 10.5527/wjn.v15.i3.120318
Table 4 Bone mineral density among the studied groups, n (%)/mean ± SD
| Variables | Inactive LN group (n = 50) | Active LN group (n = 50) | P value |
| Dual-energy X-ray absorptiometry scan (g/cm2) | 0.56 ± 0.16 | 0.42 ± 0.19 | < 0.001 |
| T score | - 0.36 ± 0.15 | -1.53 ± 0.18 | < 0.001 |
| Z score | - 0.28 ± 0.14 | -1.49 ± 0.22 | < 0.001 |
| Class of BMD | < 0.001 | ||
| Normal BMD | 37 (74) | 10 (20) | |
| Low BMD | 13 (26) | 40 (80) |
- Citation: Azoz NM, Ammar AA, Nafady HA, Gadelkareem RA, Abdel Aziz EM, Elzohne RA. Role of fibroblast growth factor-23 in renal disease activity and bone density involvement in patients with lupus nephritis. World J Nephrol 2026; 15(3): 120318
- URL: https://www.wjgnet.com/2220-6124/full/v15/i3/120318.htm
- DOI: https://dx.doi.org/10.5527/wjn.v15.i3.120318